Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma
In the JAVELIN Renal 101 trial, avelumab + axitinib showed longer PFS, higher ORR, and more durable responses vs sunitinib in aRCC patients, with manageable safety.
Related Clinical Trials
Highlighted Terms
Kindai University Faculty of MedicineMedical University of ViennaVanderbilt-Ingram Cancer CenterNetherlands Cancer InstituteavelumabAsan Medical CenterDana-Farber Cancer InstituteNiigata University Graduate School of Medicinesunitinibadvanced renal cell carcinomaBeatson West of Scotland Cancer CentreInstitut Gustave RoussyCity of HopeaxitinibNCT02684006University of LyonHospital Universitario Dr. Jose Eleuterio GonzalezIstituto Europeo di OncologiaCentre Léon BérardEuromedserviceDepartment of Clinical MedicineAmsterdam UMCRoyal Marsden NHS Foundation TrustGeorgetown University Medical CenterPfizerMemorial Sloan Kettering Cancer CenterThe University of Texas MD Anderson Cancer CenterThe Chaim Sheba Medical CenterEMD Serono Research & Development InstituteMerck Healthcare KGaABC Cancer - Vancouver Centre
Related News
Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma
In the JAVELIN Renal 101 trial, avelumab + axitinib showed longer PFS, higher ORR, and more durable responses vs sunitinib in aRCC patients, with manageable safety.